A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases

被引:0
作者
Tatsuaki Takeda
Shiho Sugimoto
Jun Matsumoto
Naohiro Iwata
Akihiko Nakamoto
Aya Fukuma Ozaki
Hirofumi Hamano
Noritaka Ariyoshi
Yoshito Zamami
机构
[1] Okayama University,Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences
[2] Okayama University Hospital,Department of Pharmacy
[3] Okayama University,Department of Personalized Medicine and Preventive Healthcare Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences
[4] University of California,Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences
来源
International Journal of Clinical Pharmacy | 2024年 / 46卷
关键词
Abemaciclib; Adverse event; Breast cancer; Cyclin-dependent kinase 4/6 inhibitor; Palbociclib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:536 / 541
页数:5
相关论文
共 45 条
[1]  
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-49
[2]  
Ferlay J(2019)Breast cancer treatment: a review JAMA 321 288-300
[3]  
Siegel RL(2016)Palbociclib and letrozole in advanced Breast cancer N Engl J Med 375 1925-36
[4]  
Waks AG(2018)Overall survival with palbociclib and fulvestrant in advanced Breast cancer N Engl J Med 379 1926-36
[5]  
Winer EP(2020)The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative Breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial JAMA Oncol 6 116-24
[6]  
Finn RS(2017)MONARCH 3: abemaciclib as initial therapy for advanced Breast cancer J Clin Oncol 35 3638-46
[7]  
Martin M(2020)Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-Positive, High-Risk, early Breast Cancer (monarchE) J Clin Oncol 38 3987-98
[8]  
Rugo HS(2023)Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early Breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Lancet Oncol 24 77-90
[9]  
Turner NC(2020)Zero-cell corrections in random-effects meta-analyses Res Synth Methods 11 913-19
[10]  
Slamon DJ(2013)Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics Bone Marrow Transplant 48 452-8